These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 15271401)
1. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Qazilbash MH; Giralt SA; Champlin RE Hematol Oncol Clin North Am; 2004 Jun; 18(3):703-13, xi. PubMed ID: 15271401 [TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. Shimoni A; Nagler A Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553 [TBL] [Abstract][Full Text] [Related]
4. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R Clin Transpl; 2003; ():275-82. PubMed ID: 15387119 [TBL] [Abstract][Full Text] [Related]
5. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia]. Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801 [TBL] [Abstract][Full Text] [Related]
6. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Foss FM Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113 [TBL] [Abstract][Full Text] [Related]